How Aspirin Causes Bleeding
Aspirin triggers bleeding primarily by irreversibly inhibiting cyclooxygenase-1 (COX-1), a key enzyme in platelets that produces thromboxane A2 (TXA2). TXA2 normally promotes platelet aggregation and vasoconstriction to form clots at injury sites. Once inhibited, platelets cannot regenerate TXA2 for their 7-10 day lifespan, impairing primary hemostasis and extending bleeding time.[1][2]
Why Platelets Are Uniquely Affected
Platelets lack nuclei, so they cannot synthesize new COX-1 protein. A single low dose (e.g., 81 mg) acetylates 90-95% of COX-1 in circulating platelets within hours, with effects lasting until new platelets form. This creates a cumulative antiplatelet effect with repeated dosing.[1][3]
Role in Secondary Hemostasis and Vascular Effects
Aspirin has minimal direct impact on coagulation factors or fibrin formation. High doses may mildly inhibit endothelial prostacyclin (PGI2) production, which normally opposes TXA2, but platelet inhibition dominates. It also reduces von Willebrand factor release in some cases, worsening bleeding in susceptible patients.[2][4]
Common Bleeding Sites and Risk Factors
Gastrointestinal bleeding occurs most often due to local COX-1 inhibition in mucosa, reducing protective prostaglandins and increasing ulcer risk. Other sites include skin (easy bruising), nose (epistaxis), and surgical wounds. Risks rise with age >65, concurrent anticoagulants (e.g., warfarin), alcohol use, H. pylori infection, or doses >325 mg/day.[1][5]
How Long Effects Last and Reversal Options
Antiplatelet effects persist 7-10 days after the last dose, matching platelet turnover. Platelet transfusion reverses it acutely; desmopressin or tranexamic acid helps in mild cases. No specific antidote exists, unlike for direct oral anticoagulants.[3][4]
Comparison to Other Antiplatelets
Unlike reversible inhibitors like clopidogrel (P2Y12 blocker) or ticagrelor, aspirin's irreversible COX-1 action affects all pathways involving TXA2. Dual therapy (aspirin + P2Y12 inhibitor) amplifies risk, as seen in trials like PLATO.[2][5]
[1]: PubMed - Aspirin and platelets
[2]: NEJM - Mechanism of aspirin's antiplatelet action
[3]: Circulation - Duration of aspirin's effect
[4]: Blood - Aspirin reversal strategies
[5]: Gastroenterology - GI bleeding risks